Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 4/20 | 0.39 |
| ▸ | GABRD | O14764 | 4/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.39 |
| ▸ | GABRE | P78334 | 4/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL996399 | 1.00 | SLC7A5 (0.53) | SLC7A5ACHETP53SLC1A3SLC1A2 | |
| Alanine SCHEMBL996694 | 1.00 | SLC7A5 (0.53) | SLC7A5ACHETP53SLC1A3SLC1A2 | |
| Alanine SCHEMBL14764702 | 0.93 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL2027760 | 0.93 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL2784274 | 0.93 | — | — | |
| Alanine SCHEMBL452350 | 0.93 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL1332110 | 0.93 | — | — | |
| D-Alanine SCHEMBL614024 | 0.93 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL254290 | 0.93 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL31 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-30 | — | — | US | claimed |
| WO-2009092073-A2 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-23 | — | — | WO | claimed |
| US-20090186832-A1 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | SHIRE LLC (US) | 2009-07-23 | — | — | US | claimed |
| WO-2009092071-A2 | AMINO ACID AND PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | SHIRE LLC (US) | 2009-07-23 | — | — | WO | claimed |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | SHIRE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2453900-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007247-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009092073-A2 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | SLC7A5 41/4885ACHE 72/4885TP53 3970/4885 |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | OPRL1, OPRM1, DNPEP | SLC7A5 44/4885ACHE 71/4885TP53 4169/4885 |
| US-20090186832-A1 | AMINO ACID PEPTIDE PRO-DRUGS OF PHENOLIC ANALGESICS AND USES THEREOF | DNPEP, PEPD, PREP | SLC7A5 47/4885ACHE 62/4885TP53 1810/4885 |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | OPRL1, OGFR, OPRK1 | SLC7A5 49/4885ACHE 225/4885TP53 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.